Values First Advisors Inc. Buys 19,568 Shares of Agenus Inc. (NASDAQ:AGEN)

Values First Advisors Inc. boosted its holdings in Agenus Inc. (NASDAQ:AGEN) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 269,829 shares of the biotechnology company’s stock after buying an additional 19,568 shares during the quarter. Values First Advisors Inc. owned approximately 0.07% of Agenus worth $223,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in AGEN. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter valued at approximately $25,000. Commonwealth Equity Services LLC acquired a new stake in Agenus during the 3rd quarter valued at approximately $26,000. Sei Investments Co. acquired a new stake in shares of Agenus during the 1st quarter worth approximately $28,000. SG Americas Securities LLC acquired a new stake in shares of Agenus during the 3rd quarter worth approximately $36,000. Finally, Two Sigma Securities LLC grew its position in shares of Agenus by 116.9% during the 2nd quarter. Two Sigma Securities LLC now owns 22,750 shares of the biotechnology company’s stock worth $36,000 after buying an additional 12,263 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

AGEN stock traded up $0.02 during midday trading on Thursday, hitting $0.58. The company had a trading volume of 5,492,624 shares, compared to its average volume of 10,264,015. Agenus Inc. has a 52 week low of $0.49 and a 52 week high of $2.13. The stock’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.80.

Insider Buying and Selling at Agenus

In related news, insider Garo H. Armen acquired 500,000 shares of the stock in a transaction on Thursday, February 15th. The stock was purchased at an average price of $0.65 per share, for a total transaction of $325,000.00. Following the completion of the transaction, the insider now owns 625,969 shares of the company’s stock, valued at approximately $406,879.85. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AGEN shares. B. Riley cut their target price on Agenus from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, March 18th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Agenus in a research note on Thursday, March 14th. Finally, StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Sunday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.10.

Agenus Profile

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.